December 9, 2019
Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial
Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.